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Abstract: 
A simple, sensitive and rapid spectrofluorimetricImethod was developed and validated for the determination of 
Gemifloxacin mesylate (GFX), in bulk powder, pharmaceutical preparations and biological fluids. The proposed method 
was based on complexation of GFX with AlCl3 as complexing agent then measuring the fluorescence of the resulted 
complex after enhancement with sodium dodecyl sulphate (SDS) in borate buffer (pH 8) at emission wavelength of 401 
nm after excitation at 264 nm. Different experimental parameters affecting relative fluorescence intensity (RFI) were 
carefully studied  and optimized  to  obtain  the maximum  relative  fluorescence  intensity. The  developed method   was 
validated according to International Conference on Harmonisation guidelines in terms of specificity, linearity, lower limit 
of quantification (LOQ) 0.54 ng.mI
-1
, lower limit of detection (LOD) 0.18 ng.mI
-1
, accuracy and precision. The 
proposed method was found to be rectilinear over the concentration range of 1-20 ng.mI
-1 
with recovery  percentage  of  
99.85±0.84. The proposed method was applied successfully for the determination of GFX in pharmaceutical 
preparations  and spiked human  plasma  with  recovery percentage  of  99.97±0.79  and 99.96±1.73  respectively.  The 
results were statistically analyzed and compared with a reference method and no significance difference was found 
between both methods. 
Keywords: Gemifloxacin mesylate, Spectrofluorimetry, AlCl3, SDS, Complexation, Pharmaceutical preparations and 
Biological Flulds. 
Introduction: 
GFX is chemicaIIy structured ((R, S)-7-[(4Z)-3-(aminomethyI)-4-(methoxyimino)-1-pyrroIidinyI]-1-cycIopropyI-6- 
fIuoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyIic acid methanesuIfonate Fig. 1. It is a fourth generation synthetic 
fIuorinated quinoIone antibacteriaI agent. Itiis present in twoiforms, either as free GFX base or as GFX mesyIate saIt [1]. 
GFX has a broad spectrum antibacteriaI activity againstigram-positive and gram-negative organisms due to its duaI 
mechanism of action by inhibition of both DNA gyrase and topoisomerase IV enzymes. The 4-oxo-3 carboxyIic acid 
group is essentiaI for the antibacteriaI activity, because they mediate binding to the DNA-gyrase compIex [2]. 
SeveraI methods were decIared for determination of GFX in pharmaceuticaI preparations or human pIasma incIuding: 
spectrophotometry [3-8], spectrofIuorimetry [9-12] capiIIary eIectrophoresis [13, 14], HPIC methods [8, 15-20] and   HPTlC 
methods [16, 21-23]. 
Among avaiIabIe methods for determination of drugs, spectrofIuorimetry is considered the most popuIar technique for 
determination of pharmaceuticaI compounds due to its simpIicity, specificity and Iow cost. 
Objective of the work: 
The purpose of this method is to establish a simple, sensitive and rapid spectrofluorimetric method for 
determination of GFX by complexation with Al
+3 
and enhancement of fluorescence intensity of the formed complex by 
addition of SDS. The proposed method was validated according to lCH guidelines and also applied for determination of 
GFX in tablets and spiked plasma. 
Experimental 
Appapratus: 
 Spectrofluorimetric analysis were carried out on a RF-1501 Shimadzu spectrofluorimeter with a Xenon arc 
lamp, and a 1cm quartz cell. 
 A ConsortiP-901 pH-meter was used for pH measurements. 
Reagents and Materials: 
AII the chemicals used were of analytical reagent grade, and the solvents were of spectroscopic grade. 
 GFX was kindly supplied by Medizin Pharmaceutical Company (Borg Elarab, Alexandria, Egypt) and its 
pharmaceutical preparation Quinabiotic Tablets, with Batch No: 12625 were obtained from local pharmacy. 
 Aqueous  solution  of  AlCl3   (1×10
-3
M),  SDS  0.5%  with   99%  purity   were  supplied  from  Park  Scientific  
limited, Northampton, UK. Borate buffer (0.2 M), acetate buffer (0.2 M). 
 Human plasma was provided by Mansoura University Hospitals (Mansoura, Egypt) and kept frozen until used 
after gentle thawing. 
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Sample preparation and procedures: 
Stock solution of GFX mesylate (100 µg.mI
-1
) was prepared by dissolving 10 mg GFX in 100 ml measuring 
flask and the volume was completed to 100 ml with distilled water. Serial dilutions were performed to cover the working 
range. 
Procedures: 
Construction of calibration curve: 
Into a series οf 10 ml vοlumetric flasks, transfer aliquots οf the wοrking solution (100 ng.ml
-1
) so as to obtain 
drug concentration in the range of 1-20 ng.ml
-1
. Add 1.2 ml (1×10
-3 
M) AlCl3, 2 mI οf bοrate buffer (pH 8) then add 0.5 
ml of SDS (0.5%), shake well and leave the solution for 20 min at room temprature. Complete to volume with borate 
buffer and measure the resulting flourescence intensity at emission wavelength 401 nm after excitation at 264 nm, plot 
the concentration versus RFI to obtain the standard calibration curve. 
Procedure for tablets dosage form: 
Five tablets are ground to a fine powder, transfer a weighed amount οf the powdered tablets equivalent to 10 
mg of the drug intο a 100 ml volumetric flask, then mix with 50 ml distilled water and sonicate the flask fοr 30 min. Dilute 
the solution to the mark with distilled water, mix well and filter. Prepare serial dilutions cοvering the wοrking 
concentration range of 1-20 ng.ml
-1
. Standard addition method was applied as follow: 
Adding a known amount of pure drug at three different concentrations 1, 4, 6 ng.ml
-1 
to a previously analyzed tablet 
solution at three different concentrations 1, 2, 3 ng.ml
-1
. The cοncentrations mentiοned of the pure drug added in 
separate flasks to each of the mentioned tablet concentration and the solution was reanalyzed for the total drug content. 
The fluorescence intensity is then measured for all solutions and the data is plotted against concentration of the standard 
added, linear regression is performed and the slope and intercept of the calibration curve are used to calculate the 
unknown concentration of analyte in the provided sample. 
Assay of GFX in spiked human plasma: 
Transfer 1 ml of plasma sample into centrifugation tube then add 1 ml of the studied compound containing 100 
µg.ml
-1
. Shake well for 3 min, then extract with 3×5 ml of acetonitrile for protein denaturation. Shake the mixture on a 
vortex mixer for 30 second, and centrifuge for 12 min at 4000 rpm in a microcentrifuge. Transfer the protein free 
supernatant into 25 ml volumetric flask and dilute to the mark with distilled water and then proceed as described under 
“construction of calibration curve”. 
Results and discussion: 
GFX exhibits strong intense native fluorescence in Acetonitrile at” 401 nm after excitation at 264 nm. 
Complexation of GFX with Al
+3 
results in increase in RFI upon adding SDS (0.5%) and borate buffer pH 8 there is 
enhancement of RFI  by 100%  Fig. 2,  The complex is formed through binding of  Al
+3  
to  the    carbonyl and 
carboxylate oxygen of the drug which is essential for activity, forming six-membered ring as shown in Fig. 3. On the 
other hand, the piprazinyl substituent has a natural chair conformation which is not favorable for fluorescence. 
Protonation of piperzinyl nitrogen stabiIizes planar configuration, therefore both binding effect of Al
+3  
and protonation of 
piprazinyl imino group lead to a stable planar structure and extended π-electron resonance, which enhances 
fluorescence properties of the drug. [24] 
Different experimental parameters affecting RFI of GFX were carefully studied and optimized, each factor was changed 
individually which others were kept constant as follow: 
Effect of pH: The effect of pH on RFI was studied using acetate and borate buffers. It was found that higher RFI was 
obtained in alkaline pH. By using different pH values of 0.2 M borate buffer it was observed that; pH 8 gave the 
maximum RFI, and at higher pH values there was a sharp decrease in RFI as shown in Fig. 4. So pH 8 was the optimum 
pH for measurement throughout the whole work. 
Effect of AlCl3 Volumes: By changing the volume of AlCl3 (1×10
-3
M) it was found that 1.2 ml gave the maximum RFI 
as shown in Fig. 5. 
Effect of SDS Concentration: RFI of the reaction product of GFX and Al
+3 
was enhanced by addition of SDS. By using 
different SDS concentration, it was observed that 0.5 ml of 0.5% SDS was the optimum for obtaining maximum RFI as 
shown in Fig. 6, also in absence of SDS there was a sharp decrease in RFI of the resulting complex. 
Effect of reaction time: The maximum RFI was obtained after 15 minutes and remained constant for 60 minutes, so 20 
minute was selected as optimum reaction time and used throughout the whole method. 
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Stoichiometry of the reaction : 
The stoichiometry of the reaction was studied by using limiting logarithmic method [25]. The two straight lines 
obtained using increasing concentrations of the reagent while keeping the concentration of the drug constant and using 
increasing concentration of drug while keeping the concentration of the reagent constant. Plots of log [RFI] versus log 
[GFX] and log [AlCl3] gave two straight lines, the value of their slope were 0.2 for GFX and 0.21 for AlCl3 Fig. 7a, 7b. 
Hence, it is concluded that the reaction proceeds in ratio of 1:1 confirming that one molecule of GFX reacts with one 
molecuIe of the Al
+3
. 
VaIidation of the proposed method: 
The proposed method was validated through the validation criteria including: linearity, sensitivity (detection limit 
& quantitation limit), specificity, accuracy, intraday and ineterday precision, and robustness. 
Linearity: Linear relationship was obtained for GFX by plotting RFI against drug concentrations. Linear relationship was 
obtained over the concentration range cited in (Table 1). Linear regression analysis of the data by the proposed methods 
gave the following equation: 
RFI = 88.77 + 31.64C   (r =0.9999) 
Where RFI is the relative fluorescence intensity, C is drug concentration (ng/ml) and   r  is correlation coefficient. 
The data were analyzed statistically [26] giving acceptable high value of the correlation coefficient (r) of the regression 
equation, small values of the standard deviation of residuals (Sy/x), intercepts (Sa), and slopes (Sb), and small values of 
the percentage relative standard deviation and  percentage relative errors. 
The Sensitivity of method was evaluated by determination of limit of detection (LOD) and limit of quantitation (LOQ) 
according to lCH guidelines [27]. 
LOD was evaluated by determination minimum amount of the analyte in the sample which can be detected but not 
necessarily quantitated as an exact value; on the other hand IOQ was evaluated by determination of the minimum 
amount of the analyte in the sample which can be quantitatively determined with suitable precision and accuracy. Both 
LOQ and LOD were calculated using the following equations and the results were presented in (Table 1): 
LOQ = 10 Sa /b and LOD = 3.3 Sa /b 
Where Sa = standard deviation of the intercept and b = sIope of the calibration curve. 
Accuracy and precision: The results of the assay of GFX were compared with those obtained by the comparison 
method [12] which is based on measurement of native fluorescence of GFX in isopropanol at 400 nm after excitation at 
272 nm. Statistical analysis of the results using student‟s t-test and variance ratio F-test proved that there was no 
significant difference between the performance of the proposed and comparison methods regarding the accuracy and 
precision, respectively (Table 2). The intraday and interday precision for the reaction was obtained by analysis of the 
samples at 3 different concentrations in one day and for three successive days, and the results were cited in (Table3). 
Robustness of the method is evaluated by the regularity of the RFI with minor changes in experimental variables. Such 
as time of reaction (20±2 min) volume of AlCl3 (1.2±0.2 ml). These minor changes of parameters didn’t affect the RFI. 
Assay of the dosage forms: 
Standard addition method was applied to establish the concentration of the analyte that is in a complex matrix, 
due to presence of other components that interfere with the analyte signal causing inaccuracy in the determined 
concentration (Table 4). 
Assay of spiked plasma: 
The proposed method was applied for the determination of GFX in biological fluids, the results are summarized  
in (Table 5). 
Conclusions: 
SimpIe, sensitive and rapid spectroflourimetric method was established for determination of GFX in tablet and 
spiked plasma through complexation with AlCl3 as complexing agent. The proposed method was validated according to 
lCH guidelines. 
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TabIes: 
TabIe 1. AnaIyticaIiperformance data for the spectrofIuorimetric determinationiof GFX by theiproposed method: 
Parameteri ResuIts 
WaveIenght λex/λem nm 264/401 
Linearity range (ng/mI) 1-20 
Intercept(a) 88.77 
Slope(b) 31.64 
Correlation coefficient(r) 0.9999 
SD  of residuals (Sy/x) 2.54 
SD  of intercept (Sa) 1.72 
I S S N  2 3 2 1 - 8 0 7 X  
V o I u m e  1 2  N u m b e r 2 1  
J o u r n a I  o f  A d v a n c e s  i n  C h e m i s t r y  
5303 | P a g e                                                                             
D e c e m b e r  2 0 1 6                                             w w w . c i r w o r I d . c o m  
SD  of sIope (Sb) 0.15 
%RSD 0.84 
%Error 0.29 
LOD (ng/ml) 0.18 
LOQ (ng/ml) 0.54 
TabIe (2): AssayiresuIts for the spectrofIuorimetricidetermination of GFX inipure form by theiproposed and 
comparisonimethods 
Pure form 
% Found
 
of  Drugs 
Proposed method Comparison method 
 
98.72 100.97 
98.96 99.03 
100.75 100.19 
100.85  
99.64  
100.30  
99.15  
100.40  
Meani() ±iS.D. 99.85 ± 0.84 100.06 ± 0.98 
it-test 0.37 (2.26) 
iF-vaIuei 1.36 (19.35) 
 
TabIe (3):iAccuracy and precision data for the determination of GFX iniPure form by theiproposed method: 
Parameter 
GFXiconcentration (ng.mI
-1
) 
8 10 14 
In
tr
a
d
a
y
 
Mean () 100.58 98.06 102.41 
S.D. 0.46 0.32 0.69 
% RSDi 0.45 0.32 0.67 
% Errori 0.26 0.19 0.39 
In
te
rd
a
y
 
Meani() 100.98 97.85 102.03 
S.D. 0.60 0.66 0.47 
% RSDi 0.59 0.67 0.46 
% Errori 0.35 0.39 0.27 
TabIe (4): Assay resuIts for theidetermination of GFX in its tabIetidosageiform by theiproposed andicomparison 
methods: 
Dosage form 
% Found
 
 
iProposed method iComparison method 
(12)
 
 
99.20 100.89 
100.77 99.11 
99.93 100.318 
iMean () ± S.D. 99.97 ± 0.79 100.06± 0.89 
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it-test 0.14 (2.78) 
iF-vaIue 1.30 (19.00) 
 
TabIe (5):iAssayiresuIts for theidetermination of GFX inispiked human pIasma using theiproposed 
spectrofIuorometricimethod 
 
Amountitaken 
(ng/mI) 
Amountifound 
(ng/mI) 
%iFound 
 
 
8 
 
7.88 
 
98.46 
 10 10.19 
 
101.86 
 14 13.94 
 
99.57 
 Mean ()   99.96 
 ± SD   ± 1.73 
% RSD   1.74 
 % Error   1.001 
 Figures: 
 
  
 
           Fig. (1): Structural formula of GFX. 
 
Fig. (2): (a, a’) excitation and emission spectra of GFX-Al
+3
-SDS complex (10 ng.ml
-1
) while (b, b’) excitation 
and emission spectra of GFX in acetonitrile, (c, c’) excitation and emission spectra of GFX-Al
+3 
complex and 
(d,d’) excitation and emission spectra of blank(SDS-Al
+3
). 
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Fig. (3): Formation of Drug-Al
+3 
complex. 
p H  v a lu e s
R
FI
6 7 8 9 1 0 1 1
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
 
Fig. (4): Effectiof pH on the fluorescent product of GFX (10 ng.mI
-1
) Al
+3
-SDS. 
V o lu m e  o f  A lC l3 ( 1 × 1 0
- 3
 M )
R
F
I
0 .0 0 .5 1 .0 1 .5 2 .0 2 .5
2 5 0
3 0 0
3 5 0
4 0 0
4 5 0
 
Fig. (5): Effectiof different volume of AlCl3 (1×10
-3
 M) on fluorescent intenisty of the reaction with GFX  (10 ng.ml
-1
) 
upon using 0.5 ml 0.5% SDS and Borate buffer (pH 8). 
V o lu m e  o f  S D S  (0 .5 % )
R
F
I
0 .0 0 .5 1 .0 1 .5 2 .0 2 .5 3 .0 3 .5
2 5 0
3 0 0
3 5 0
4 0 0
4 5 0
 
Fig. (6): Effect of SDS volume (0.5%) on fluorescence intensity of the reaction with GFX (10 ng.mI
-1
) upon using 
1.2 mI AlCl3 (1×10
-3
) and borate buffer (pH 8). 
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Fig. 7a 
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Fig. 7b 
Fig.i(7): Limitingilogarithmiciplots forimolar ratio. (a)ilog RFIivs. logI[GFX] with log [AlCl3] kepticonstant. (b)Ilog 
RFI vs. log [AlCl3] with log [GFX] kept constant. 
 
 
